These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30864295)

  • 1. Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients.
    Wang X; Kong Y; Chi Z; Sheng X; Cui C; Mao L; Lian B; Tang B; Yan X; Si L; Guo J
    Thorac Cancer; 2019 Apr; 10(4):950-956. PubMed ID: 30864295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab: A Review in Advanced Melanoma.
    Scott LJ
    Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
    JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary malignant melanoma of the esophagus: a study of clinical features, pathology, management and prognosis.
    Yu H; Huang XY; Li Y; Xie X; Zhou JL; Zhang LJ; Fu JH; Wang X
    Dis Esophagus; 2011 Feb; 24(2):109-13. PubMed ID: 21040150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and surgical outcomes for primary malignant melanoma of the esophagus: a single-center experience.
    Wang S; Tachimori Y; Hokamura N; Igaki H; Kishino T; Kushima R
    Ann Thorac Surg; 2013 Sep; 96(3):1002-6. PubMed ID: 23810175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive clinicopathological and molecular analysis of primary malignant melanoma of the oesophagus.
    Tsuyama S; Kohsaka S; Hayashi T; Suehara Y; Hashimoto T; Kajiyama Y; Tsurumaru M; Ueno T; Mano H; Yao T; Saito T
    Histopathology; 2021 Jan; 78(2):240-251. PubMed ID: 32654197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of esophagectomy for primary malignant melanoma of the esophagus: a single-institute retrospective analysis.
    Harada K; Mine S; Yamada K; Shigaki H; Oya S; Baba H; Watanabe M
    Dis Esophagus; 2016 May; 29(4):314-9. PubMed ID: 25708974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and prognosis of primary malignant melanoma of the esophagus.
    Chen H; Fu Q; Sun K
    Medicine (Baltimore); 2020 Jul; 99(28):e20957. PubMed ID: 32664098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological characteristics, staging classification, and survival outcomes of primary malignant melanoma of the esophagus.
    Sun H; Gong L; Zhao G; Zhan H; Meng B; Yu Z; Pan Z
    J Surg Oncol; 2018 Mar; 117(4):588-596. PubMed ID: 29266237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines.
    Guan X; Wang H; Ma F; Qian H; Yi Z; Xu B
    Medicine (Baltimore); 2016 Mar; 95(11):e3134. PubMed ID: 26986169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.
    Amini-Adle M; Khanafer N; Le-Bouar M; Duru G; Dalle S; Thomas L
    BMC Cancer; 2018 Jul; 18(1):705. PubMed ID: 29970025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications.
    Dai J; Jia J; Zhang F; Liu K; Xi Y; Yuan P; Mao L; Bai X; Wei X; Wang B; Li J; Xu Y; Liu T; Chang S; Shao Y; Guo J; Ying J; Si L
    Cancer Res Commun; 2024 May; 4(5):1351-1362. PubMed ID: 38695555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
    Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
    Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy.
    Dai J; Bai X; Gao X; Tang L; Chen Y; Sun L; Wei X; Li C; Qi Z; Kong Y; Cui C; Chi Z; Sheng X; Xu Z; Lian B; Li S; Yan X; Tang B; Zhou L; Wang X; Xia X; Guo J; Mao L; Si L
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36593066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
    Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
    Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
    Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
    Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary malignant melanoma of the esophagus: long-term survival following pre- and postoperative adjuvant hormone/chemotherapy.
    Uetsuka H; Naomoto Y; Fujiwara T; Shirakawa Y; Noguchi H; Yamatsuji T; Haisa M; Matsuoka J; Gunduz M; Takubo K; Tanaka N
    Dig Dis Sci; 2004 Oct; 49(10):1646-51. PubMed ID: 15573920
    [No Abstract]   [Full Text] [Related]  

  • 19. Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma.
    Aya F; Gaba L; Victoria I; Fernández-Martínez A; Tosca M; Prat A; Arance A
    Future Oncol; 2016 Dec; 12(23):2683-2688. PubMed ID: 27581765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
    Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.